Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibition

Cancer Discovery

Volumn 6, Issue 11, 2016, Pages 1248-1257

  Scott, Mary T ^a,b   Korfi, Koorosh ^a,b   Saffrey, Peter ^a   Hopcroft, Lisa E M ^b   Kinstrie, Ross ^a   Pellicano, Francesca ^b   Guenther, Carla ^a,b   Gallipoli, Paolo ^b   Cruz, Michelle ^a   Dunn, Karen ^b   Jorgensen, Heather G ^b   Cassels, Jennifer E ^b   Hamilton, Ashley ^b   Crossan, Andrew ^a   Sinclair, Amy ^b   Holyoake, Tessa L ^b   Vetrie, David ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CD38 ANTIGEN; CD45 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; PROTEIN TYROSINE KINASE INHIBITOR; TRANSCRIPTION FACTOR EZH2; BCR ABL PROTEIN; EZH2 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ANIMAL CELL; APOPTOSIS ASSAY; ARTICLE; CANCER STEM CELL; CELL ASSAY; CELL CULTURE; CELL DIFFERENTIATION ASSAY; CELL PROLIFERATION ASSAY; CHRONIC MYELOID LEUKEMIA; COMPARATIVE STUDY; COMPUTATIONAL ANALYSIS; DIAGNOSTIC PROCEDURE; DNA MICROARRAY; EPIGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; MOLECULAR GENETICS; MOUSE; NONHUMAN; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; DRUG EFFECTS; DRUG RESISTANCE; GENETIC EPIGENESIS; GENETICS; HEMATOPOIETIC STEM CELL; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METABOLISM; NUCLEAR REPROGRAMMING; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELLULAR REPROGRAMMING; DRUG RESISTANCE, NEOPLASM; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; EPIGENESIS, GENETIC; FUSION PROTEINS, BCR-ABL; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; NEOPLASTIC STEM CELLS; PROTEIN KINASE INHIBITORS;

EID: 84995451794     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-16-0263     Document Type: Article

References (27)

1. Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013; 122: 515-22.
2. Hamilton A, Helgason GV, Schemionek M, Zhang B, Myssina S, Allan EK, et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 2012; 119: 1501-10.
3. Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2011; 121: 396-409.
4. Gerber JM, Qin L, Kowalski J, Smith BD, Griffin CA, Vala MS, et al. Characterization of chronic myeloid leukemia stem cells. Am J Hematol 2011; 86: 31-7.
5. Nieborowska-Skorska M, Kopinski PK, Ray R, Hoser G, Ngaba D, Flis S, et al. Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood 2012; 119: 4253-63.
6. Chu S, McDonald T, Lin A, Chakraborty S, Huang Q, Snyder DS, et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood 2011; 118: 5565-72.
7. Chomel JC, Bonnet ML, Sorel N, Bertrand A, Meunier MC, Fichelson S, et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood 2011; 118: 3657-60.
8. Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature 2011; 469: 343-9.
9. Lund K, Adams PD, Copland M. EZH2 in normal and malignant hematopoiesis. Leukemia 2014; 28: 44-9.
10. Crea F, Paolicchi E, Marquez VE, Danesi R. Polycomb genes and cancer: Time for clinical application? Crit Rev Oncol Hematol 2012; 83: 184-93.
11. Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010; 42: 722-6.
12. Schmidt M, Rinke J, Schafer V, Schnittger S, Kohlmann A, Obstfelder E, et al. Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status. Leukemia 2014; 28: 2292-9.
13. Herrera-Merchan A, Arranz L, Ligos JM, de Molina A, Dominguez O, Gonzalez S. Ectopic expression of the histone methyltransferase Ezh2 in haematopoietic stem cells causes myeloproliferative disease. Nat Commun 2012; 3: 623.
14. Hidalgo I, Herrera-Merchan A, Ligos Jose M, Carramolino L, Nuñez J, Martinez F, et al. Ezh1 is required for hematopoietic stem cell maintenance and prevents senescence-like cell cycle arrest. Cell Stem Cell 2012; 11: 649-62.
15. Xie H, Xu J, Hsu JH, Nguyen M, Fujiwara Y, Peng C, et al. Polycomb repressive complex 2 regulates normal hematopoietic stem cell function in a developmental-stage-specific manner. Cell Stem Cell 2014; 14: 68-80.
16. Verma SK, Tian X, LaFrance LV, Duquenne C, Suarez DP, Newlander KA, et al. Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2. ACS Med Chem Lett 2012; 3: 1091-6.
17. Holyoake T, Jiang X, Eaves C, Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 1999; 94: 2056-64.
18. Hamad A, Sahli Z, El Sabban M, Mouteirik M, Nasr R. Emerging therapeutic strategies for targeting chronic myeloid leukemia stem cells. Stem Cells Int 2013; 2013: 724360.
19. Pellicano F, Sinclair A, Holyoake TL. In search of CML stem cells’ deadly weakness. Curr Hematol Malig Rep 2011; 6: 82-7.
20. Knutson SK, Kawano S, Minoshima Y, Warholic NM, Huang KC, Xiao Y, et al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol Cancer Ther 2014; 13: 842-54.
21. Pellicano F, Scott MT, Helgason GV, Hopcroft LE, Allan EK, Aspinall-O’Dea M, et al. The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors. Stem Cells 2014; 32: 2324-37.
22. Hurtz C, Hatzi K, Cerchietti L, Braig M, Park E, Kim YM, et al. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J Exp Med 2011; 208: 2163-74.
23. Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 2012; 118: 3123-7.
24. Xie H, Peng C, Huang J, Li BE, Kim W, Smith EC, et al. Chronic myelogenous leukemia-initiating cells require Polycomb group protein EZH2. Cancer Discov 2016; 6: 1237-47.
25. Dhami P, Saffrey P, Bruce AW, Dillon SC, Chiang K, Bonhoure N, et al. Complex exon-intron marking by histone modifications is not determined solely by nucleosome distribution. PLoS One 2010; 5: e12339.
26. Ye T, Krebs AR, Choukrallah MA, Keime C, Plewniak F, Davidson I, et al. seqMINER: an integrated ChIP-seq data interpretation platform. Nucleic Acids Res 2011; 39: e35.
27. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998; 95: 14863-8.